Skip to main content

Table 1 Patient Characteristics

From: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899

  Arm A (n = 32) Arm B (n = 31) Total (n = 63)
  n Percent n Percent n Percent
Age       
   Median   70   65   68
   Range   50-89   45-80   45-89
Race       
   White 30 94% 28 90% 58 92%
   Black 1 3% 3 10% 4 6%
   Hispanic 1 3% 0 0% 1 2%
ECOG PS       
   0 15 47% 17 55% 32 51%
   1 16 50% 12 39% 28 44%
   2 1 3% 2 6% 3 5%
Extent of Disease       
   Measurable, Non-Osseous Disease Present 14 44% 13 42% 27 43%
   Evaluable, Osseous Disease Present 28 88% 30 97% 58 92%
   Evaluable, Non-Osseous Disease Present 13 41% 12 39% 25 40%
   Elevated PSA 32 100% 30 97% 62 98%
Metastatic Disease       
   Lung 4 13% 4 13% 8 13%
   Liver 3 9% 3 10% 6 10%
   Bone 28 88% 29 94% 57 90%
   Bone Marrow 0 0% 1 3% 1 2%
   Pleura 1 3% 0 0% 1 2%
   Other 11 34% 9 29% 20 32%
Prior Treatment       
   Orchiectomy 10 31% 7 23% 17 27%
   Prostatectomy 17 53% 15 48% 32 51%
   Other Surgery 19 59% 20 65% 39 62%
   Radiation Therapy 18 56% 20 65% 38 60%
   Hormonal Therapy 31 97% 29 94% 60 95%
   Biologic Response Modifier 4 13% 2 6% 6 10%